ArticleCurrent health sciences journal
Spectrum of Post Tuberculosis Chronic Lung Disease in Patients with Previous Bacteriologically Confirmed Pulmonary Tuberculosis.
Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of anti- tuberculosis (TB) drugs, in the middle of last century, did not resolve the goal of a better healing, and the most important cause is represented by delayed diagnosis of TB disease. We conducted a single-center case control study, from January, 1st, 2017 to December, 31st, 2024, including 400 adult symptomatic inpatients diagnosed with post TB lung disease (PTLD), after a previous episode of treated TB disease. There were excluded 168 patients without pulmonary function testing (PFT), those with significant occupational exposure, and/or diseases autoimmune, COVID-19 or HIV infection, which might interfere lung function assessment. All demographics, behavioral and baseline PTB characteristics (relapses, clinical, imagistic, endoscopic, microbiologic, PFT, evolution) were assessed in order to inventorying sequelae and lung damage, types of lung function impairment. Eligible patients (n=232), mean aged 60.94+/-11.895 years, males (55.17%), were divided into 129 cases with previous bacteriologically confirmed PTB (mean age 58.37+/-11.86 years; 55.81% males) and 103 controls with previous clinically diagnosed PTB (mean age 60.04+/-11.222; 54.37% males). Delayed diagnosis and relapses of PTB had greater impact on PTLD development in cases (p=0.000), as well as previous cavitary PTB (p=0.000). The risk of death, during hospitalization, was greater in cases (p=0.000). Spectrum of PTLD, in cases, was dominated by bronchiectasis (p=0.000), suppurative episodes (p=0.004), open healing cavitation (p=0.000), intracavitary aspergilloma (p=0.002), fibrothorax (p=0.000), lung function impairment (p=0.030). In conclusion, PTLD severity is related to delayed diagnosis of previous contagious PTB, permanent lung damage, impairment of lung function, having a higher risk of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.